Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo

Gynecologic Oncology

Volumn 135, Issue 1, 2014, Pages 142-148

  Schwab, Carlton L ^a   English, Diana P ^a   Roque, Dana M ^a   Bellone, Stefania ^a   Lopez, Salvatore ^b   Cocco, Emiliano ^a   Nicoletti, Roberta ^a   Rutherford, Thomas J ^a   Schwartz, Peter E ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

ErbB inhibitors; HER2 neu; Neratinib; Small tyrosine kinase inhibitors; Uterine serous carcinoma

Indexed keywords

DRUG VEHICLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NERATINIB; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; CANCER GROWTH; CARCINOMA CELL LINE; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENDOMETRIUM CARCINOMA; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CELL CYCLE; DRUG EFFECTS; FEMALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UTERINE NEOPLASMS;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; FEMALE; IN VITRO TECHNIQUES; MICE; QUINOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; UTERINE NEOPLASMS;

EID: 84907977042     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.08.006     Document Type: Article

References (32)

1. American Cancer Society Cancer facts and figs. 2014 2014 American Cancer Society Atlanta, GA
2. K.N. Moore, and A.N. Fader Uterine papillary serous carcinoma Clin Obstet Gynecol 54 2011 278 291
3. S.F. Lax Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification Virchows Arch 444 2004 213 223
4. A.S. Felix, J.L. Weissfeld, R.A. Stone, R. Bowser, M. Chivukula, and R.P. Edwards Factors associated with type I and type II endometrial cancer Cancer Causes Control 21 2010 1851 1856
5. S. Acharya, M.L. Hensley, A.C. Montag, and G.F. Fleming Rare uterine cancers Lancet Oncol 6 2005 961 971
6. S. Zhao, M. Choi, J.D. Overton, S. Bellone, D.M. Roque, and E. Cocco Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma Proc Natl Acad Sci U S A 110 2013 2916 2921
7. M. Le Gallo, A.J. O'Hara, M.L. Rudd, M.E. Urick, N.F. Hansen, and N.J. O'Neil Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes Nat Genet 44 2012 1310 1315
8. R.B. Cohen Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC) Cancer Treat Rev 40 2014 567 577
9. M. Roengvoraphoj, G.J. Tsongalis, K.H. Dragnev, and J.R. Rigas Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients Cancer Treat Rev 39 2013 839 850
10. D.P. English, D.M. Roque, and A.D. Santin HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies Mol Diagn Ther 17 2013 85 99
11. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 2005 341 354
12. N. Buza, D.P. English, A.D. Santin, and P. Hui Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice Mod Pathol 26 2013 1605 1612
13. C. Wright, B. Angus, S. Nicholson, J.R. Sainsbury, J. Cairns, and W.J. Gullick Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer Cancer Res 49 1989 2087 2090
14. A. Berchuck, A. Kamel, R. Whitaker, B. Kerns, G. Olt, and R. Kinney Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer Cancer Res 50 1990 4087 4091
15. D.J. Hetzel, T.O. Wilson, G.L. Keeney, P.C. Roche, S.S. Cha, and K.C. Podratz HER-2/neu expression: a major prognostic factor in endometrial cancer Gynecol Oncol 47 1992 179 185
16. M. Tanner, M. Hollmen, T.T. Junttila, A.I. Kapanen, S. Tommola, and Y. Soini Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 2005 273 278
17. I.B. Engelsen, I.M. Stefansson, R. Beroukhim, W.R. Sellers, M. Meyerson, and L.A. Akslen HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas Int J Oncol 32 2008 307 316
18. Z. Hartman, H. Zhao, and Y.M. Agazie HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling Oncogene 32 2013 4169 4180
19. D.P. English, S. Bellone, E. Cocco, I. Bortolomai, S. Pecorelli, and S. Lopez Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of class I PI3 kinase and mTOR kinase (TORC1/2) Am J Obstet Gynecol 209 2013 465 e1-9
20. S.K. Rabindran, C.M. Discafani, E.C. Rosfjord, M. Baxter, M.B. Floyd, and J. Golas Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase Cancer Res 64 2004 3958 3965
21. K.K. Wong, P.M. Fracasso, R.M. Bukowski, T.J. Lynch, P.N. Munster, and G.I. Shapiro A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors Clin Cancer Res 15 2009 2552 2558
22. A.D. Santin, S. Bellone, M. Gokden, M. Palmieri, D. Dunn, and J. Agha Overexpression of HER-2/neu in uterine serous papillary cancer Clin Cancer Res 8 2002 1271 1279
23. G.F. Fleming, M.W. Sill, K.M. Darcy, D.S. McMeekin, J.T. Thigpen, and L.M. Adler Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 116 2010 15 20
24. M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, and J. Cortes Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer J Natl Cancer Inst 99 2007 628 638
25. W.B. Growden, V. Byron, C. DiGloria, D. Borger, R. Foster, and J. Winslow HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant Reprod Sci 21 2014 94A
26. P. Todeschini, E. Cocco, S. Bellone, J. Varughese, K. Lin, and L. Carrara Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab Br J Cancer 105 2011 1176 1182
27. A. Canonici, M. Gijsen, M. Mullooly, R. Bennett, N. Bouguern, and K. Pedersen Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer Oncotarget 4 2013 1592 1605
28. A. Wissner, E. Wissner, M. Overbeek, M.B. Reich, B. Floyd, and N. Johnson Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2) J Med Chem 46 2003 49 63
29. H.R. Tsou, E.G. Overbeek-Klumpers, W.A. Hallett, M.F. Reich, M.B. Floyd, and B.D. Johnson Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J Med Chem 48 2005 1107 1131
30. H. Ji, D. Li, L. Chen, T. Shimamura, S. Kobayashi, and K. McNamara The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies Cancer Cell 9 2006 485 495
31. H.J. Burstein, Y. Sun, L.Y. Dirix, Z. Jiang, R. Paridaens, and A.R. Tan Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer J Clin Oncol 28 2010 1301 1307
32. R. Abbas, B.A. Hug, C. Leister, and D. Sonnichsen A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor Cancer Chemother Pharmacol 70 2012 191 199